Nipocalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FcRn |
| Clinical data | |
| Trade names | Imaavy |
| Other names | nipocalimab-aahu |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6266H9722N1670O1992S46 |
| Molar mass | 141797.16 g·mol−1 |
Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis.[1] It is a neonatal Fc receptor blocker.[1] It is an high affinity, fully human, aglycosylated, effectorless immunoglobulin G (IgG) anti-FcRn monoclonal antibody.[2][3]
Nipocalimab was approved for medical use in the United States in April 2025.[4][5]
- ^ a b c "Imaavy- nipocalimab injection, solution, concentrate". DailyMed. 6 May 2025. Retrieved 24 June 2025.
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page). - ^ Seth NP, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S, et al. (December 2025). "Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties". mAbs. 17 (1): 2461191. doi:10.1080/19420862.2025.2461191. PMC 11834464. PMID 39936406.
- ^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 1 May 2025. Archived from the original on 3 March 2025. Retrieved 1 May 2025.
- ^ "Johnson & Johnson receives FDA approval for Imaavy (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)" (Press release). Johnson & Johnson. 30 April 2025. Archived from the original on 1 May 2025. Retrieved 1 May 2025 – via MultiVu.